Progyny (NASDAQ:PGNY – Free Report) had its target price boosted by KeyCorp from $45.00 to $50.00 in a research report released on Friday morning, Marketbeat Ratings reports. KeyCorp currently has an overweight rating on the stock. KeyCorp also issued estimates for Progyny’s Q3 2023 earnings at $0.10 EPS, Q4 2023 earnings at $0.10 EPS, FY2023 […]
Progyny (NASDAQ:PGNY – Get Free Report) released its quarterly earnings data on Thursday. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.10 by $0.05, Briefing.com reports. The firm had revenue of $279.40 million for the quarter, compared to analyst estimates of $261.91 million. Progyny had a net margin […]
Progyny (NASDAQ:PGNY – Get Free Report) issued its quarterly earnings results on Thursday. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.05, Briefing.com reports. The business had revenue of $279.40 million for the quarter, compared to analysts’ expectations of $261.91 million. Progyny had a net […]
Shares of Progyny, Inc. (NASDAQ:PGNY – Get Free Report) have earned an average rating of “Moderate Buy” from the six research firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective […]
Pacer Advisors Inc. lessened its stake in Progyny, Inc. (NASDAQ:PGNY – Free Report) by 41.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,460 shares of the company’s stock after selling 5,956 shares during the period. Pacer Advisors Inc.’s holdings in Progyny were […]